S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:TARA

Protara Therapeutics Competitors

$13.75
-2.30 (-14.33 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.51
Now: $13.75
$16.01
50-Day Range
$16.05
MA: $19.43
$22.44
52-Week Range
$12.51
Now: $13.75
$67.08
Volume217,394 shs
Average Volume93,749 shs
Market Capitalization$154.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Competitors

Protara Therapeutics (NASDAQ:TARA) Vs. AGEN, DTIL, PSTX, CGEN, DBVT, and CRIS

Should you be buying TARA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Protara Therapeutics, including Agenus (AGEN), Precision BioSciences (DTIL), Poseida Therapeutics (PSTX), Compugen (CGEN), DBV Technologies (DBVT), and Curis (CRIS).

Protara Therapeutics (NASDAQ:TARA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Protara Therapeutics and Agenus, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protara Therapeutics00303.00
Agenus00303.00

Protara Therapeutics currently has a consensus target price of $47.6667, indicating a potential upside of 246.67%. Agenus has a consensus target price of $8.00, indicating a potential upside of 153.16%. Given Protara Therapeutics' higher possible upside, research analysts clearly believe Protara Therapeutics is more favorable than Agenus.

Institutional & Insider Ownership

83.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 53.4% of Agenus shares are held by institutional investors. 45.7% of Protara Therapeutics shares are held by insiders. Comparatively, 4.7% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Protara Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares Protara Therapeutics and Agenus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protara TherapeuticsN/A-45.45%-41.09%
Agenus-192.56%N/A-97.02%

Earnings & Valuation

This table compares Protara Therapeutics and Agenus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A
Agenus$150.05 million4.00$-107,660,000.00($0.80)-3.95

Protara Therapeutics has higher earnings, but lower revenue than Agenus.

Summary

Protara Therapeutics beats Agenus on 6 of the 9 factors compared between the two stocks.

Protara Therapeutics (NASDAQ:TARA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Protara Therapeutics and Precision BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protara Therapeutics00303.00
Precision BioSciences02402.67

Protara Therapeutics currently has a consensus price target of $47.6667, suggesting a potential upside of 246.67%. Precision BioSciences has a consensus price target of $20.00, suggesting a potential upside of 81.49%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Precision BioSciences.

Earnings and Valuation

This table compares Protara Therapeutics and Precision BioSciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A
Precision BioSciences$22.24 million26.00$-92,880,000.00($1.91)-5.77

Protara Therapeutics has higher earnings, but lower revenue than Precision BioSciences.

Insider & Institutional Ownership

83.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of Precision BioSciences shares are owned by institutional investors. 45.7% of Protara Therapeutics shares are owned by company insiders. Comparatively, 14.3% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Protara Therapeutics and Precision BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protara TherapeuticsN/A-45.45%-41.09%
Precision BioSciences-484.81%-105.74%-53.08%

Risk & Volatility

Protara Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

Summary

Protara Therapeutics beats Precision BioSciences on 8 of the 11 factors compared between the two stocks.

Poseida Therapeutics (NASDAQ:PSTX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Insider & Institutional Ownership

41.1% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are owned by institutional investors. 19.0% of Poseida Therapeutics shares are owned by company insiders. Comparatively, 45.7% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Poseida Therapeutics and Protara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
Protara TherapeuticsN/A-45.45%-41.09%

Earnings & Valuation

This table compares Poseida Therapeutics and Protara Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.35
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Poseida Therapeutics and Protara Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
Protara Therapeutics00303.00

Poseida Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 169.40%. Protara Therapeutics has a consensus price target of $47.6667, suggesting a potential upside of 246.67%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Poseida Therapeutics.

Summary

Protara Therapeutics beats Poseida Therapeutics on 3 of the 5 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 45.7% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Compugen has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Valuation & Earnings

This table compares Compugen and Protara Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A

Protara Therapeutics has lower revenue, but higher earnings than Compugen.

Profitability

This table compares Compugen and Protara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CompugenN/A-26.98%-23.28%
Protara TherapeuticsN/A-45.45%-41.09%

Analyst Ratings

This is a summary of current recommendations for Compugen and Protara Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Compugen00703.00
Protara Therapeutics00303.00

Compugen currently has a consensus target price of $20.7143, suggesting a potential upside of 153.85%. Protara Therapeutics has a consensus target price of $47.6667, suggesting a potential upside of 246.67%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Compugen.

Summary

Compugen beats Protara Therapeutics on 5 of the 9 factors compared between the two stocks.

Protara Therapeutics (NASDAQ:TARA) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Protara Therapeutics and DBV Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protara Therapeutics00303.00
DBV Technologies24302.11

Protara Therapeutics currently has a consensus target price of $47.6667, suggesting a potential upside of 246.67%. DBV Technologies has a consensus target price of $7.0714, suggesting a potential upside of 40.87%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than DBV Technologies.

Earnings & Valuation

This table compares Protara Therapeutics and DBV Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A
DBV Technologies$14.75 million37.39$-172,020,000.00($2.33)-2.15

Protara Therapeutics has higher earnings, but lower revenue than DBV Technologies.

Profitability

This table compares Protara Therapeutics and DBV Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protara TherapeuticsN/A-45.45%-41.09%
DBV TechnologiesN/AN/AN/A

Risk and Volatility

Protara Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500.

Institutional & Insider Ownership

83.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of DBV Technologies shares are owned by institutional investors. 45.7% of Protara Therapeutics shares are owned by company insiders. Comparatively, 15.3% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Protara Therapeutics beats DBV Technologies on 5 of the 9 factors compared between the two stocks.

Protara Therapeutics (NASDAQ:TARA) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Profitability

This table compares Protara Therapeutics and Curis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protara TherapeuticsN/A-45.45%-41.09%
Curis-279.33%N/A-81.32%

Analyst Ratings

This is a breakdown of current recommendations for Protara Therapeutics and Curis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protara Therapeutics00303.00
Curis00303.00

Protara Therapeutics presently has a consensus target price of $47.6667, indicating a potential upside of 246.67%. Curis has a consensus target price of $12.00, indicating a potential upside of 31.43%. Given Protara Therapeutics' higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Curis.

Institutional and Insider Ownership

83.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 34.7% of Curis shares are held by institutional investors. 45.7% of Protara Therapeutics shares are held by company insiders. Comparatively, 7.3% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Protara Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500.

Earnings & Valuation

This table compares Protara Therapeutics and Curis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A
Curis$10 million53.70$-32,140,000.00($0.86)-10.62

Protara Therapeutics has higher earnings, but lower revenue than Curis.

Summary

Protara Therapeutics beats Curis on 6 of the 9 factors compared between the two stocks.


Protara Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
Axcella Health logo
AXLA
Axcella Health
1.6$5.51-3.1%$206.85 millionN/A-2.56
INmune Bio logo
INMB
INmune Bio
1.5$15.37-22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43-6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
Genfit logo
GNFT
Genfit
1.3$4.87-2.7%$189.24 million$45.88 million-2.47
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.18-6.7%$186.70 millionN/A-8.76Gap Up
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$4.23-14.2%$178.75 million$1.45 million-1.48Earnings Announcement
Analyst Upgrade
Increase in Short Interest
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.90-0.7%$178.60 millionN/A-2.27Gap Up
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$5.35-4.3%$168.68 million$20,000.000.00Decrease in Short Interest
Gap Down
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.5$13.01-19.3%$166.26 million$2.33 million0.00Upcoming Earnings
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.1$11.70-0.9%$156.42 million$32.12 million-90.00Upcoming Earnings
News Coverage
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$14.65-2.2%$149.81 millionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.18-6.1%$149.52 millionN/A-2.87Earnings Announcement
News Coverage
Gap Up
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.63-10.3%$140.75 millionN/A-1.81
Dyadic International logo
DYAI
Dyadic International
1.3$4.94-4.0%$135.76 million$1.68 million-14.53
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.75-3.6%$130.06 million$23.05 million-2.11Upcoming Earnings
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.9$8.15-2.6%$126.15 million$3 million-2.62Increase in Short Interest
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.